Endothelial TFEB (Transcription Factor EB) Restrains IKK (IκB Kinase)-p65 Pathway to Attenuate Vascular Inflammation in Diabetic db/db Mice.
Animals
Aorta
/ metabolism
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
/ physiology
Cell Adhesion
Diabetes Mellitus, Type 2
/ genetics
Diabetic Angiopathies
/ metabolism
Endothelial Cells
/ metabolism
Gene Expression Regulation
/ physiology
Human Umbilical Vein Endothelial Cells
Humans
I-kappa B Kinase
/ physiology
Inflammation
Kruppel-Like Transcription Factors
/ physiology
Male
Mice, Inbred C57BL
Mice, Knockout
Mice, Mutant Strains
Physical Conditioning, Animal
Receptors, Leptin
/ deficiency
Recombinant Proteins
/ metabolism
Signal Transduction
/ physiology
Transcription Factor RelA
/ physiology
Transcription, Genetic
chemokines
diabetes mellitus
endothelial cells
monocytes
phosphorylation
Journal
Arteriosclerosis, thrombosis, and vascular biology
ISSN: 1524-4636
Titre abrégé: Arterioscler Thromb Vasc Biol
Pays: United States
ID NLM: 9505803
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
pubmed:
1
3
2019
medline:
14
1
2020
entrez:
1
3
2019
Statut:
ppublish
Résumé
Objective- TFEB (transcription factor EB) was recently reported to be induced by atheroprotective laminar flow and play an anti-atherosclerotic role by inhibiting inflammation in endothelial cells (ECs). This study aims to investigate whether TFEB regulates endothelial inflammation in diabetic db/db mice and the molecular mechanisms involved. Approach and Results- Endothelial denudation shows that TFEB is mainly expressed in ECs in mouse aortas. Western blotting shows TFEB total protein level decreases whereas the p-TFEB S142 (phosphorylated form of TFEB) increases in db/db mouse aortas, suggesting a decreased TFEB activity. Adenoviral TFEB overexpression reduces endothelial inflammation as evidenced by decreased expression of vascular inflammatory markers in db/db mouse aortas, and reduced expression of a wide range of adhesion molecules and chemokines in human umbilical vein ECs. Monocyte attachment assay shows TFEB suppresses monocyte adhesion to human umbilical vein ECs. RNA sequencing of TFEB-overexpressed human umbilical vein ECs suggested TFEB inhibits NF-κB (nuclear factor-kappa B) signaling. Indeed, luciferase assay shows TFEB suppresses NF-κB transcriptional activity. Mechanistically, TFEB suppresses IKK (IκB kinase) activity to protect IκB-α from degradation, leading to reduced p65 nuclear translocation. Inhibition of IKK by PS-1145 abolished TFEB silencing-induced inflammation in human umbilical vein ECs. Lastly, we identified KLF2 (Krüppel-like factor 2) upregulates TFEB expression and promoter activity. Laminar flow experiment showed that KLF2 is required for TFEB induction by laminar flow and TFEB is an anti-inflammatory effector downstream of laminar flow-KLF2 signaling in ECs. Conclusions- These findings suggest that TFEB exerts anti-inflammatory effects in diabetic mice and such function in ECs is achieved by inhibiting IKK activity and increasing IκBα level to suppress NF-κB activity. KLF2 mediates TFEB upregulation in response to laminar flow.
Identifiants
pubmed: 30816805
doi: 10.1161/ATVBAHA.119.312316
doi:
Substances chimiques
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
0
Klf2 protein, mouse
0
Kruppel-Like Transcription Factors
0
RELA protein, human
0
Receptors, Leptin
0
Recombinant Proteins
0
Rela protein, mouse
0
TFEB protein, human
0
Tcfeb protein, mouse
0
Transcription Factor RelA
0
leptin receptor, mouse
0
I-kappa B Kinase
EC 2.7.11.10
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM